product and service
continuous experimentation!
Commercial – APIs
Active Pharmaceutical Ingredient - APIs
Under-Development APIs
Commercial KSMs, Intermediates & Reagents
|
Product Name |
CAS No. |
Structure |
End Use |
|
Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate |
5398-36-7 |
|
ACOTIAMIDE HCL HYDRATE |
|
2,4,5-Trimethoxy Benzoic Acid |
490-64-2 |
|
ACOTIAMIDE HCL HYDRATE |
|
Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate |
185105-98-0 |
|
ACOTIAMIDE HCL HYDRATE |
|
5,6-Dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperidinyl)phenyl]-2(1H)-pyridinone(KSM) |
545445-44-1 |
|
APIXABAN |
|
3-AMINO-3-IMINOPROPANOIC ACID 1-(DIPHENYLMETHYL)-3-AZETIDINYL ESTER ACETATE |
170749-59-4 |
|
AZELNIDIPINE |
|
ISOPROPYL 2-(3-NITROBENZYLIDENE)ACETOACETATE |
39562-25-9 |
|
AZELNIDIPINE |
|
1-benzhydryl-3-azetidinyl amidinoacetate |
116574-09-5 |
|
AZELNIDIPINE |
|
2-(2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)propan-2-yl)-4,4-dimethyl-4,5-dihydrooxazole |
202189-77-3 |
|
BILASTINE |
|
(R)-4-PROPYLDIHYDROFURAN-2-(3H) |
63095-51-2 |
|
BRIVARACETAM |
|
Choline phosphate chloride calcium (Calcium phosphorylcholine chloride) |
4826-71-5 |
|
CITICOLINE SODIUM |
|
D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl) methyl]phenyl]-, 2,3,4,6-tetraacetate, (1S) |
461432-25-7 |
|
DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE |
|
Ethyl 1-(6-amino-3,5-difluoro-2-pyridinyl)-6-fluoro-1,4-dihydro-7-[3-(2-methyl-1-oxopropoxy)-1-azetidinyl]-4-oxo-3-quinolinecarboxylate |
442526-91-2 |
|
DELAFLOXACIN MEGLUMINE |
|
ABT- 492 Meglumine |
352458-37-8 |
|
DELAFLOXACIN MEGLUMINE |
|
2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone |
32384-65-9 |
|
EMPAGLIFLOZIN / DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE |
|
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one |
247257-48-3 |
|
FIMASARTAN TRIHYDRATE POTASSIUM |
|
2-(2-butyl-4-hydroxy-6-Methylpyrimidin-5-yl)-N,N-dimethylacetamide (Fima-Pyrimidinamide) |
1315478-13-7 |
|
FIMASARTAN TRIHYDRATE POTASSIUM |
|
(S)-N-ethyl-2-aminomethyl pyrrolidine |
22795-99-9 |
|
LEVOSULPIRIDE |
|
Pyrrolidine,1-ethyl-2-(nitromethyl) |
26171-04-0 |
|
LEVOSULPIRIDE |
|
(1R), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-ol |
114446-57-0 |
|
LULICONAZOLE |
|
1-(Cyanomethyl) Imidazole Hydrochloride |
220476-15-3 |
|
LULICONAZOLE |
|
Imidazole 1-acetonitrile Mesylate |
not assigned |
|
LULICONAZOLE |
|
2-Aminothiazol-4-yl) Acetic acid |
29676-71-9 |
|
MIRABEGRON |
|
(R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide |
521284-19-5 |
|
MIRABEGRON |
|
(R)-2-[[2'-(4-nitropheny])-ethyl]amino]-1-phenylethanol monohydrochloride |
521284-21-9 |
|
MIRABEGRON |
|
(1R)-2-{[2-(4-Aminophenyl)ethyl]amino}-1-phenylethanol hydrochloride (1:1) |
521284-22-0 |
|
MIRABEGRON |
|
Uridine, 4-oxime |
3258-02-4 |
|
MOLNUPIRAVIR |
|
3alpha-hydroxy-6-ethylidene-7keto-5beta cholanoic acid |
1885104-64-2 |
|
OBETICHOLIC ACID |
|
1-(3-methoxypropyl)piperidin-4-amine |
179474-79-4 |
|
PRUCALOPRIDE SUCCINATE |
|
4-amino-5-chloro-2,3-dihydro-1-benzofuran-7-carboxylic acid |
123654-26-2 |
|
PRUCALOPRIDE SUCCINATE |
|
2-{(2R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl) aniline] propyl}-1-H-isoindole-1,3(2H)-dione |
446292-07-5 |
|
RIVAROXABAN |
|
1-H isoindole-1,3-(2H)-dione, Â 2-[[(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]- |
446292-08-6 |
|
RIVAROXABAN |
|
(S)-4-[4-[5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholin-3-one hydrochloride |
898543-06-1 |
|
RIVAROXABAN |
|
(2S)-4-oxo-2-(3-thiazolidinyl carbonyl)-1-pyrrolidine carboxylic acid Tert-butyl ester |
401564-36-1 |
|
TENELIGLIPTIN HYDROBROMIDE HYDRATE |
|
1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine |
401566-79-8 |
|
TENELIGLIPTIN HYDROBROMIDE HYDRATE |
|
(2S)-1-(Chloroacetyl)-2- pyrrolidine-carbonitrile (Vila-Nitrile) |
207557-35-5 |
|
VILDAGLIPTIN |
|
Lawesson’s reagent |
19172-47-5 |
|
      FIMASARTAN |
Under-development KSMs, Intermediates & Reagents
|
Product Name |
CAS No. |
Structure |
End Use |
Status |
|
N,N-Diisopropyl Ethylene diamine |
7087-68-5 |
|
ACOTIAMIDE HCL HYDRATE |
|
|
1,4-DIHYDRO-26-DIMETHYL-4-(3-NITROPHENYL)-35-PYRIDINEDICARBOXYLIC ACID 3-METHYL ESTER |
74936-72-4 |
|
BENIDIPINE HYDROCHLORIDE |
|
|
N-BENZYL-3-HYDROXYPIPERIDINE |
14813-01-5 |
|
BENIDIPINE HYDROCHLORIDE |
|
|
2-(4-(1-(4,4-dimethyl-∆2-oxazoline-2-yl)-1-methylethyl)phenyl)ethyl p-toluene sulphonate. |
202189-76-2 |
|
BILASTINE |
|
|
5-bromo-2-chloro-4'-ethoxydiphenylmethane |
461432-23-5 |
|
DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE |
|
|
4-(5-bromo-2-chloro-benzyl)-phenol |
864070-18-8 |
|
EMPAGLIFLOZIN |
|
|
(R)-3-(4-methylphenylsulfonyloxy)-tetrahydrofuran |
219823-47-9 |
|
EMPAGLIFLOZIN |
|
|
N-Amino-3-Azabicyclo(3.3.0)Octane hydrochloride |
58108-05-7 |
|
GLICLAZIDE |
|
|
Trans-(4-methylcyclohexyl) amine HCL Â (CHH) |
33483-65-7 |
|
GLIMEPIRIDE |
|
|
3-Ethyl-4-methyl-l, 5-dihydro-1H-pyrrol-2-one |
766-36-9 |
|
GLIMEPIRIDE |
|
|
2-phenylethyl isocyanate |
1943-82-4 |
|
GLIMEPIRIDE |
|
|
8-Bromo-3-methyl-xanthine |
93703-24-3 |
|
LINAGLIPTIN |
|
|
1-Bromo-but-2-yne |
3355-28-0 |
|
LINAGLIPTIN |
|
|
2-(chloromethyl)-4-methylquinazoline |
109113-72-6 |
|
LINAGLIPTIN |
|
|
(R)-3-tert-Butoxycarbonylaminopiperidine |
309956-78-3 |
|
LINAGLIPTIN |
|
|
2,4,5-Trifluorobenzeneacetic acid |
209995-38-0 |
|
SITAGLIPTIN |
|
|
3-(trifluoromethyl)-5,6,7,8-tetrahydro [1,2,4]triazolo[4,3-a]pyrazine HCl |
762240-92-6 |
|
SITAGLIPTIN |
|
|
2-{[(3aR,4S,6R,6aS)-6-{[5-Amino-6-chloro-2-(propylsulfanyl)-4-pyr imidinyl]amino}-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]diox ol-4-yl]oxy}ethanol |
376608-74-1 |
|
TICAGRELOR |
|
|
4,6-dichloro-2-(propylthio)-pyrimidin-5-amine |
145783-15-9 |
|
TICAGRELOR |
|
|
2,4-dimethylbenzenethiol |
13616-82-5 |
|
VORTIOXETINE HBr |
|
|
2-bromonitrobenzene |
577-19-5 |
|
VORTIOXETINE HBr |
|
|
(1R,2S)-2-(3,4-difluorophenyl)-cyclopropan aminium-(2R)-hydroxy (phenyl)ethanoate |
376608-71-8 |
|
TICAGRELOR |
|
|
n-Butyl Lithium |
109-72-8 |
|
DAPAGLIFLOZIN |
Services - CRAMS
Kimia Biosciences offers Contract Research and Manufacturing and Development Services across the entire value chain of a new chemical entity which covers from Pre-Clinical to Commercial Phase. We have a strong and dynamic team of scientists functioning from research centers, which are supported by a highly compliant manufacturing footprint with robust multi-product facilities.
As an imminent CRO-CDMO player, we envisaged to work with India and global innovator pharma companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.
Robust Supply Chain
1. Comfort to customers with a backward integrated setup that ensures supply assurance of the key intermediates.
2. Scalable infrastructure to counter supply chain oversights going forward
3. Work with clients in flexible, adaptable and customized partnership model for small molecules.
Quality Committed
1. Committed to deliver services with sustain focus on quality, affordable innovation and productivity
One Stop Solution for your Chemical Needs
1. Offering services from mg to metric ton scale
2. We cover the entire life cycle of a new chemical entity at all scales, from pre-clinical and clinical phases to validation and commercial supply, while fully complying with cGMP regulations and standards within WHO GMP, FDA approved facilities.
Environment, Health and Safety
1. We comply with all applicable EHS Legal and other requirements
2. We optimize our resources in a way to prevent and reduce pollution, energy consumption and to increase water conservation.
OUR UPCOMING SERVICES:
Chemistry, manufacturing and controls
Kimia Biosciences has a strong team of scientists and process engineers. We are up to any challenge involving complex chemical synthesis, from route scouting, process development, and scale-up to commercial scale.
As a contract manufacturing organisation (CMO), we make high-quality APIs and intermediates that serve the highly regulated markets of the USA, Europe, and Japan etc. Our world-class manufacturing facilities are equipped with flexible and versatile infrastructure, and we are continuously striving to make it better.
 Services
1. Route Scouting
2. Establishing innovative Route of Synthesis (ROS) from an idea to a sustainable process
3. Process familiarisation, optimisation & development
4. Phase-appropriate process development to ensure successful scale-up and timely product delivery for your clinical trials
5. Analytical method development & validation
6. Phase-appropriate analytical methods using complementing techniques
7. Process safety evaluation
8. Rigorous, data-driven Process Safety evaluation
9. Stability studies
10. Comprehensive range of stability services across time zones
11. Early phase scale-up
Discovery
Kimia Biosciences is a trusted small molecule CRO partner envisaged to help innovator Pharma companies accelerate their drug discovery journey from HIT to IND using creative chemistry supported by high quality , DMPK, toxicology and cGMP scale-up services.
We are known to be responsive, flexible and cost-effective in delivering solutions tailored to suit the program requirements. Our strong and growing scientific team provides a fully-integrated service bringing the collective expertise of various teams together to develop a lead candidate.
 Services
1. Integrated Drug Discovery Services
2. Discovery services spanning the entire journey from target ID and validation to IND
3. Synthetic & medicinal chemistry
4. Specializing in the synthesis of complex chemical entities to advance your drug discovery programs
5. DMPK: In vitro ADME
6. Expediting compound profiling from hit to candidate
7. DMPK: In vivo PK
8. Pharmacokinetic (PK) speed and flexibility to accelerate your decision making
- Important Links
KIMIA BIOSCIENCE LIMITED
974, Aggarwal Millennium Tower II,
Netaji Subhash Place, Pitampura,
New Delhi-110 034
+91-11-4706 3600
info@kimiabiosciences.com
Kimia Biosciences Ltdâ„¢ is engaged in manufacturing of bulk drugs addressing to various high potential therapeutic segments and has envisaged high growth plans through infrastructure creation and CMS.